Streptozocin
Alkylating Agent
DB00428
Approved Indication
For the treatment of malignant neoplasms of pancreas (metastatic islet cell carcinoma).
2
Targets
0
Resistance Mutations
5
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Although its mechanism of action is not completely clear, streptozocin is known to inhibit DNA synthesis, interfere with biochemical reactions of NAD and NADH, and inhibit some enzymes involved in gluconeogenesis. Its activity appears to occur as a result of formation of methylcarbonium ions, which alkylate or bind with many intracellular molecular structures including nucleic acids. Its cytotoxic action is probably due to cross-linking of strands of DNA, resulting in inhibition of DNA synthesis.
Details
DrugBank ID
DB00428 ↗
Approval Date
2003-12-03
Molecular Weight
265.2206 g/mol
Drug Class
Alkylating Agent
ATC Codes
L01AD04
Synonyms
Estreptozocina, Streptozocin, Streptozocine
PubChem
CID: 29327 ↗
ChEMBL
CHEMBL1603 ↗
SMILES
CN(N=O)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O
ADMET Profile
Computing properties…
Drug References (DrugBank)